Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Pathogenesis
Fructose 1,6-bisphosphatase inhibitors may provide therapy options for type 2 diabetes
August 7th, 2006
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. According to recent research published in the journal Diabetes, "Gluconeogenesis is increased in type 2 diabetes and contributes significantly to fasting and postprandial hyperglycemia. We recently reported the discovery of the first potent and selective inhibitors of fructose 1,6-bisphosphatase (FBPase), a rate-controlling enzyme of gluconeogenesis." "Herein," proposed P.D. van Poelje and associates at Metabasis Therapeutic, "we describe acute and chronic effects of the lead inhibitor, MB06322...
Source: Gastroenterology Week (2006-08-07)
|
